Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Hypertension

Mixed Results for Omecamtiv Mecarbil in Heart Failure Study

Diana Ernst, RPh

October 14, 2020

Findings showed the study met the primary end point of reduction in cardiovascular death or heart failure events.

Men's Health Update

AstraZeneca Pauses COVID-19 Vaccine Trials

Diana Ernst, RPh

September 10, 2020

In a statement, the Company noted that the actions being taken are considered “routine” when an unexplained illness is reported in a clinical trial.

Diabetes

Semglee Now Available for Patients With Diabetes

Diana Ernst, RPh

September 4, 2020

The long-acting human insulin analogue has an identical amino acid sequence to Lantus® (insulin glargine; Sanofi).

Prostate Cancer

FDA Approves Blood-Based Test as Companion Diagnostic for Multiple Cancer Drugs

Diana Ernst, RPh

August 31, 2020

Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.

Men's Health Update

Emergency Use Authorization Issued for COVID-19 Convalescent Plasma

Diana Ernst, RPh

August 25, 2020

The EUA was based on historical evidence indicating some effectiveness with convalescent plasma use in previous outbreaks of respiratory viruses, preclinical data, results from small clinical trials, and data from the National Expanded Access Treatment Protocol sponsored by the Mayo Clinic.

Diabetes

Managing SGLT2 Inhibitor-Associated Genital Mycotic Infections

Diana Ernst, RPh

August 20, 2020

Genital mycotic infection is listed as a potential adverse effect of the SGLT2 inhibitor class.

Men's Health Update

Comparative Analysis Shows Remdesivir Cuts Death Risk in Severe COVID-19

Diana Ernst, RPh

July 14, 2020

Treatment with remdesivir was associated with an improvement in clinical recovery and a 62% reduction in the risk of mortality in patients with severe coronavirus disease 2019.

Men's Health Update

Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins

Diana Ernst, RPh

July 7, 2020

A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

Overactive Bladder (OAB)

Vesicare LS Approved for Neurogenic Detrusor Overactivity

Diana Ernst, RPh

May 29, 2020

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

Men's Health Update

FDA Issues Statement Regarding NSAID Use and COVID-19

Diana Ernst, RPh

March 23, 2020

The FDA has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with coronavirus disease 2019 (COVID-19).

Next post in Men's Health Update